Education
About Us
Working with TipRanks
Follow Us
Rezolute (RZLT)
NASDAQ:RZLT
RZLT Stock Chart & Stats
$9.02
-$0.34(-6.35%)
At close: 4:00 PM EST
$9.02
-$0.34(-6.35%)
Day’s Range― - ―
52-Week Range$2.22 - $10.04
Previous CloseN/A
Volume107.87K
Average Volume (3M)1.50M
Market Cap
$804.74M
Enterprise Value$254.51M
Total Cash (Recent Filing)$167.86M
Total Debt (Recent Filing)$1.61M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Nov 06, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding90,828,050
10 Day Avg. Volume1,382,744
30 Day Avg. Volume1,499,465
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.21K
Enterprise Value/Ebitda-3.23
Forecast
1Y Price Target
$14.33Price Target Upside58.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical SuccessThe FDA's acceptance of sunRIZE data in cHI as confirmatory clinical evidence for tHI suggests recognition of ersodetug's efficacy across different forms of HI.
Regulatory ProgressRezolute has been gaining momentum ever since the FDA lifted the partial clinical hold on ersodetug for congenital hyperinsulinism (cHI).
Strategic ManagementThe company appointed Dr. Sunil Karnawat as Chief Commercial Officer, who has over 25 years of experience in global commercialization and has been involved in launching four products for ultra-rare diseases.
Bears Say
Capital RequirementsRezolute is likely to need to raise additional capital.
Financial HealthRezolute is not generating revenue and has capital needs that exceed current cash balance.
Study Design ConcernsThe study's original design included a double-blind arm, which would have provided more robust data but has been removed in the new alignment.
Rezolute News
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $2.21 and its highest was $10.04 in the past 12 months.
What is Rezolute’s market cap?
Rezolute’s market cap is $804.74M.
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Nov 06, 2025 which is in 13 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on Sep 17, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.219 by -$0.041.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate is -0.25.
How many shares outstanding does Rezolute have?
Rezolute has 90,828,050 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.219. Following the earnings report the stock price went up 6.355%.
Which hedge fund is a major shareholder of Rezolute?
Currently, no hedge funds are holding shares in RZLT
Rezolute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.33 (58.87% Upside)
$14.33 (58.87% Upside)
Blogger Sentiment
Bullish
RZLT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 13.3%
Last 30 Days ▲ 13.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.28%
12-Months-Change
Fundamentals
Return on Equity
-52.56%
Trailing 12-Months
Asset Growth
32.21%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc. (RZLT) is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and orphan diseases. The company is primarily engaged in the research and development of innovative treatments targeting serious conditions such as rare metabolic disorders. Its core product candidates include RZ358, an antibody designed to treat congenital hyperinsulinism, and RZ402, an oral therapy aimed at diabetic macular edema.
RZLT Stock 12 Month Forecast
Average Price Target
$14.33
▲(58.87% Upside)
Technical Analysis
Ownership Overview
10.67% Insiders
39.12% Mutual Funds
34.63% Other Institutional Investors
6.21% Public Companies and Individual Investors